Clinical application of BRAK that is anti-angiogenic agent

• Project/Area Number: 15K20567
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Surgical dentistry
• Research Institution: Kanagawa Dental College
• Principal Investigator: Ikoma Takeharu 神奈川歯科大学, 大学院歯学研究科, 助教 (10638290)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: CXCL14 / BRAK / 血管新生阻害 / 抗腫瘍効果 / サイトカイン / 血管新生抑制

Outline of Final Research Achievements

We already prepared knock-out BRAK/CXCL14 HSC-3 cell. Then, We analyzed about gene expression in HUVEC cell.We selected Gene related anti-angiogenic agent、and inplemented to Data-mining. In consequence of Data-mining, We searched relation to cardiovascular development, carbohydrate metabolism, tumor progression etc.

Research Products

• [Journal Article] Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma. (2016)
  • Author(s): Kondo T, Ozawa S, Ikoma T, Yang XY, Kanamori K, Suzuki K, Iwabuchi H, Maehata Y, Miyamoto C, Taguchi T, Kiyono T, Kubota E, Hata RI
  • Journal Title: Oncogenesis Volume: 5
  • Peer Reviewed / Open Access
• [Presentation] Is chemokine CXCL14, a multi-step tumor suppressor, a differentiation regulator of squamous epithelial cells ? (2016)
  • Author(s): T. Ikoma, X. Yang, S. Ozawa, Y. Maehata, R. Hata
  • Organizer: 歯科基礎医学会
  • Place of Presentation: 札幌
  • Year and Date: 2016-08-25
• [Presentation] Expression of the chemokine CXCL14 is a predictive biomarker for Cetuximab-dependent tumor supression. (2015)
  • Author(s): 生駒 丈晴
  • Organizer: 歯科基礎医学会
  • Place of Presentation: 新潟
  • Year and Date: 2015-09-11